Profile data is unavailable for this security.
About the company
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
- Revenue in CHF (TTM)6.57bn
- Net income in CHF636.00m
- Incorporated2002
- Employees18.69k
- LocationLonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
- Phone+41 613168111
- Fax+41 613169111
- Websitehttps://www.lonza.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qiagen NV | 1.60bn | 74.62m | 8.30bn | 5.70k | 117.82 | 3.04 | 36.38 | 5.20 | 0.3474 | 0.3474 | 7.80 | 13.46 | 0.3529 | 2.11 | 5.64 | 297,220.90 | 1.65 | 5.76 | 1.91 | 6.88 | 64.09 | 64.31 | 4.68 | 16.85 | 2.83 | -- | 0.2924 | -- | 0.6565 | 5.32 | -75.51 | -- | -9.03 | -- |
| Eurofins Scientific SE | 6.47bn | 590.83m | 10.28bn | 62.70k | 18.57 | 2.12 | 8.59 | 1.59 | 3.26 | 1.81 | 35.74 | 28.58 | 0.6384 | 38.44 | 5.00 | 110,868.30 | 6.31 | 7.65 | 7.88 | 9.53 | 22.33 | 23.95 | 9.88 | 11.41 | 1.09 | 7.95 | 0.4014 | 23.54 | 6.70 | 8.78 | 22.85 | 15.36 | 4.45 | -- |
| Genmab A/S | 2.57bn | 903.49m | 11.04bn | 2.64k | 12.23 | 2.58 | 11.46 | 4.29 | 112.77 | 112.77 | 321.18 | 533.66 | 0.5434 | 11.54 | 4.38 | 7,690,525.00 | 19.07 | 17.70 | 21.13 | 19.07 | 95.12 | -- | 35.10 | 35.77 | 5.32 | -- | 0.0263 | -- | 30.57 | 31.16 | 80.10 | 28.50 | 21.52 | -- |
| argenx SE | 2.06bn | 847.69m | 27.41bn | 1.60k | 34.96 | -- | -- | 13.34 | 13.76 | 13.76 | 34.28 | -- | -- | -- | -- | 1,380,354.00 | -- | -7.11 | -- | -7.96 | 89.73 | -- | 41.24 | -27.22 | -- | -- | -- | -- | 78.60 | 94.61 | 382.34 | -- | 7.88 | -- |
| Lonza Group AG | 6.57bn | 636.00m | 39.61bn | 18.69k | 63.22 | 4.27 | 31.92 | 6.03 | 8.92 | 8.92 | 92.21 | 132.06 | 0.3594 | 2.67 | 5.19 | 351,814.20 | 3.48 | 4.79 | 4.23 | 5.84 | 32.86 | 38.15 | 9.69 | 13.32 | 1.04 | 10.25 | 0.3341 | 32.65 | -2.13 | 9.34 | -2.75 | -0.3424 | 12.51 | 7.78 |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 30 Jun 2025 | 3.08m | 4.27% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 2.56m | 3.54% |
| Norges Bank Investment Managementas of 10 Sep 2024 | 2.17m | 3.00% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 1.32m | 1.82% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jun 2025 | 1.21m | 1.67% |
| Invesco Advisers, Inc.as of 03 Jul 2025 | 1.00m | 1.39% |
| BlackRock Investment Management (UK) Ltd.as of 04 Jul 2025 | 976.67k | 1.35% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2025 | 919.41k | 1.27% |
| Geode Capital Management LLCas of 04 Jul 2025 | 749.98k | 1.04% |
| TIAA-CREF Investment Management LLCas of 31 May 2025 | 730.16k | 1.01% |
